# Treatment Resistance Following Anti-cancer Therapies

> **NCT04436120** · NA · TERMINATED · sponsor: **Pfizer** · enrollment: 38 (actual)

## Conditions studied

- Disease Progression

## Interventions

- **PROCEDURE:** De novo tumor tissue biopsy
- **PROCEDURE:** Research blood draws

## Key facts

- **NCT ID:** NCT04436120
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-13
- **Primary completion:** 2020-12-14
- **Final completion:** 2020-12-14
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Study terminated due to lack of enrollment that has been compounded by the global COVID-19 pandemic. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04436120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04436120, "Treatment Resistance Following Anti-cancer Therapies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04436120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*